Touch Brain
Parkinson's Disease Treatment
Company Overview
Snapshot
Founded in February 2017, Touch Brain operated with 1–10 employees, focusing on novel formulations for central nervous system diseases. The company secured seed funding in November 2017 from Youdim Pharmaceuticals, marking a key early milestone in its development of intranasal drug delivery systems.
Business overview
Touch Brain specializes in developing novel formulations of existing drugs to treat large-market central nervous system diseases, particularly Parkinson's Disease. The company's core technology involves proprietary formulations for intranasal administration and unique combinations of approved drugs, aiming to leverage advantages such as increased bioavailability, elimination of first-pass metabolism, and improved brain targeting. Operating within the Health Tech & Life Sciences sector, specifically Pharma & Medical Biotechnology and Drugs Discovery & Development, Touch Brain targets the pharmaceutical industry with its R&D-stage products, including an Intra-Nasal Drug Delivery System (INDDS).
Log in to access full profile ›Company Intelligence Q&A
- What is Touch Brain's primary focus?
- Touch Brain focuses on developing novel formulations of existing drugs for the treatment of large-market central nervous system diseases, including Parkinson's Disease.
- What is the core technology behind Touch Brain's products?
- The company's core technology is based on proprietary formulations for intranasal administration and novel combinations of approved drugs, designed to enhance drug delivery to the brain.
- When was Touch Brain founded?
- Touch Brain was founded in February 2017.
- What is the current status of Touch Brain?
- Touch Brain is currently Non Active, having ceased to operate in January 2019.
- Which investor participated in Touch Brain's seed funding round?
- In November 2017, Touch Brain received seed funding from Youdim Pharmaceuticals.